跳至主要内容
临床试验/NCT00104338
NCT00104338终止2 期

A Phase 2, Proof of Concept, Randomized, Open-label, Two-arm, Parallel Group, Multi-center Study to Assess the Efficacy and Safety of FK778 Compared With Standard Care in Renal Transplant Recipients With Untreated BK Nephropathy

Astellas Pharma Inc21 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2005年1月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
45
试验地点
21
主要终点
Change from baseline in urine BK viral load

研究概览

简要总结

The purpose of this study is to assess the safety and effectiveness of a new oral immunosuppressant agent compared to standard care in renal transplant patients diagnosed with BK nephropathy.

详细描述

The purpose of this study is to assess the efficacy and safety of FK778 compared with standard care in renal transplant recipients with newly diagnosed and untreated BK nephropathy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Renal transplant recipient with newly diagnosed BK nephropathy.

排除标准

  • Previous treatment for BK nephropathy
  • Organ transplant other than kidney
  • Uncontrolled concomitant infection other than BK nephropathy

结局指标

主要结局

Change from baseline in urine BK viral load

次要结局

  • Change from baseline in plasma BK viral load
  • Change from baseline in renal function as measured by serum creatinine (SCr) and creatinine clearance (CrCl) at month 6 or at the end of therapy, whichever is earlier
  • Change from baseline in renal histology measured by Drachenberg criteria at month 6 or at the end of therapy, whichever is earlier

研究者

申办方类型
Industry

研究点 (21)

Loading locations...

相似试验